Development of a robust commercial formulation for a therapeutic protein is a complicated process and requires careful considerations of many factors, inclu
Multiple sclerosis (MS) is the archetypal model for central nervous system (CNS) autoimmunity affecting between 100 and 120 per 100,000 people in the UK.The
The continually expanding market for biotherapeutics such as recombinant proteins and antibodies that are produced in mammalian cell cultures and the relati